Renal stones von Viljoen, Adie, Chaudhry, Rabia, Bycroft, John

Volltext

Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond von Viljoen, Adie, Bain, Stephen C

Volltext

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update von Jakubowska, Agnieszka, Roux, Carel W le, Viljoen, Adie

Volltext

Plasma Levels of Middle Molecules to Estimate Residual Kidney Function in Haemodialysis without Urine Collection von Vilar, Enric, Boltiador, Capella, Wong, Jonathan, Viljoen, Adie, Machado, Ashwini, Uthayakumar, Arani, Farrington, Ken

Volltext

SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes von Wheeler, David C., James, June, Patel, Dipesh, Viljoen, Adie, Ali, Amar, Evans, Marc, Fernando, Kevin, Hicks, Debbie, Milne, Nicola, Newland-Jones, Philip, Wilding, John

Volltext

Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses von Pratley, Richard E, Aroda, Vanita R, Catarig, Andrei-Mircea, Lingvay, Ildiko, Lüdemann, Jörg, Yildirim, Emre, Viljoen, Adie

Volltext

Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, doubleblind, double-dummy, placebo-controlled, phase 3 trial von Davies, Melanie, Faerch, Louise, Jeppesen, Ole K., Pakseresht, Arash, Pedersen, Sue D., Perreault, Leigh, Rosenstock, Julio, Shimomura, Iichiro, Viljoen, Adie, Wadden, Thomas A., Lingvay, Ildiko

Volltext

A Retrospective Observational Study to Determine Baseline Characteristics and Early Prescribing Patterns for Patients Receiving Alirocumab in UK Clinical Practice von Reynolds, Tim, Carey, Peter, George, Jacob, Konidaris, Gerasimos, Narayanan, Deepa, Ramachandran, Sudarshan, Saunders, Luke, Viljoen, Adie, Ferns, Gordon

Volltext

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial von Davies, Melanie, Færch, Louise, Jeppesen, Ole K, Pakseresht, Arash, Pedersen, Sue D, Perreault, Leigh, Rosenstock, Julio, Shimomura, Iichiro, Viljoen, Adie, Wadden, Thomas A, Lingvay, Ildiko

Volltext

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial von Pratley, Richard E, Aroda, Vanita R, Lingvay, Ildiko, Lüdemann, Jörg, Andreassen, Camilla, Navarria, Andrea, Viljoen, Adie

Volltext

Diabetes and Insulin Resistance in Older People von Viljoen, Adie, MBChB, MMed, FCPath(SA), FRCPath, MBA, Sinclair, Alan J., MSc, MD, FRCP

Volltext

Safety and efficacy of rosiglitazone in the elderly diabetic patient von Viljoen, Adie, Sinclair, Alan

Volltext

Hypocalcemia following Treatment for Hyperthyroidism von MEEK, Claire L, KAPLAN, Felicity, PEREIRA, R. Scott, VILJOEN, Adie

Volltext

Vitamin D and Cardiovascular disease - dilemma, delight or 'dont know?' von Viljoen, Adie

Volltext

Renal biomarkers for the prediction of cardiovascular disease von Joshi, Supriya, Viljoen, Adie

Volltext

HEART UK consensus statement on Lipoprotein(a): A call to action von Cegla, Jaimini, Neely, R.Dermot G., France, Michael, Ferns, Gordon, Byrne, Chris D., Halcox, Julian, Datta, Dev, Capps, Nigel, Shoulders, Carol, Qureshi, Nadeem, Rees, Alan, Main, Linda, Cramb, Robert, Viljoen, Adie, Payne, Jules, Soran, Handrean

Volltext

Predicting residual kidney function in hemodialysis patients using serum β-trace protein and β2-microglobulin von Wong, Jonathan, Sridharan, Sivakumar, Berdeprado, Jocelyn, Vilar, Enric, Viljoen, Adie, Wellsted, David, Farrington, Ken

Volltext

Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised... von Lingvay, Ildiko, Catarig, Andrei-Mircea, Frias, Juan P, Kumar, Harish, Lausvig, Nanna L, le Roux, Carel W, Thielke, Desirée, Viljoen, Adie, McCrimmon, Rory J

Volltext

Elevated Lipoprotein(a): Background, Current Insights and Future Potential Therapies von Handhle, Ahmed, Viljoen, Adie, Wierzbicki, Anthony S

Volltext

Evaluation of the long‐term cost‐effectiveness of once‐weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK von Viljoen, Adie, Hoxer, Christina S., Johansen, Pierre, Malkin, Samuel, Hunt, Barnaby, Bain, Stephen C.

Volltext